Clinical Trial Update: Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM [Phase 1]

View source ↗

Summary

Phase 1 study evaluating how different fixed pramlintide-to-insulin dose ratios affect postprandial glucose in Type 1 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Insulin (insulin)
• Symlin (pramlintide)

Snippet

Sponsor: AstraZeneca | Conditions: Type 1 Diabetes | Phase 1 | Status: COMPLETED